Institut Pasteur
Also known as Fondation Institut Pasteur, Pasteur Institute
Paris biomedical research foundation; invests its endowment in listed securities, property, private equity/infrastructure funds, health seed funds and stakes in Pasteur spin-offs.
- HEADQUARTERS
- Paris, France
- FOUNDED
- 1887
- AUM
- —
- OUTSIDE CAPITAL
- No — own capital only
- TEAM LISTED
- 2 people
Focus
- STAGES
- Seed
- ASSET MIX
- Direct investmentsVenture capitalPrivate equityReal estatePublic equities
- GEOGRAPHY
- France
Overview
The Institut Pasteur is a private foundation recognised as being of public utility since its creation in 1887, working on research, public health and teaching. Its endowment policy allows up to 25% of productive assets in unlisted non-property investments (private equity, infrastructure, private debt) and up to 10% in strategic partnerships: health seed funds and stakes in start-ups founded with Pasteur researchers. At 31 December 2025 it held ten start-ups on its balance sheet, including 20.40% of the venture builder Argobio, and in 2025 it moved its venture/biotech investments into a dedicated vehicle and committed €13.0M to two new funds.
PORTFOLIO (8)
- Argobio (20.40%)Biotech & Life Sciences
- Enodia Therapeutics (34.58%; co-investor in €20.7M round, Dec 2025)Biotech & Life Sciences · since 2025
- Neurophoenix (15.00%)Biotech & Life Sciences
- Biocellis (20.00%)Biotech & Life Sciences
- V4C (22.00%)
- Avatar MedicalHealthTech
- OncovitaBiotech & Life Sciences
- genOwayBiotech & Life Sciences
People
Links
Frequently asked questions
Institut Pasteur is a institutional investor based in Paris, France, founded in 1887.
Yes. Institut Pasteur invests its own capital in private companies. It also commits capital to third-party funds as an LP.
Institut Pasteur invests at Seed stage in Biotech & Life Sciences and HealthTech.
Key people at Institut Pasteur include Yasmine Belkaid (Directrice générale) and Alban Hautier (Directeur général adjoint).
Institut Pasteur's investments include Argobio (20.40%), Enodia Therapeutics (34.58%; co-investor in €20.7M round, Dec 2025), Neurophoenix (15.00%), Biocellis (20.00%), V4C (22.00%), Avatar Medical, Oncovita and genOway.
No. Institut Pasteur invests its own capital and does not raise money from outside investors.